We specifically employed AR-null, enzalutamide-insensitive PC3 cells (Supplementary Fig. S2A) in these experiments to place emphasis on the effects of enzalutamide on the endothelium as opposed to tumor cells. This evidence concerns the gene AR and neoplasm.